Acorda Positions Ampyra For Large Market Of Post-Stroke Deficits
This article was originally published in The Pink Sheet Daily
Executive Summary
Acorda plans to move Ampyra to Phase III for treating post-stroke deficits, after reporting positive Phase II results. The company also reported a signal from a small proof-of-concept study in cerebral palsy, but next steps are unclear in that indication.